Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epoetin beta
- Development stage
- Approved
- Lead developer
- Roche
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Epoetin beta is a synthetic, recombinant form of human erythropoietin, a glycoprotein hormone that stimulates the production of red blood cells by acting on erythroid progenitor cells in the bone marrow. It is produced using Chinese hamster ovary (CHO) cells and has an identical amino acid sequence to endogenous human erythropoietin. Epoetin beta is classified as an erythropoiesis-stimulating agent (ESA) and is primarily used to treat anemia associated with chronic kidney failure and cancer chemotherapy. It increases red blood cell production by binding to the erythropoietin receptor on target cells, thereby promoting differentiation and proliferation of these precursors into mature red blood cells[5].
- Brand names
- Neorecormon
- Other names
- recombinant human erythropoietin betarHuEPO-beta
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on epoetin beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epoetin beta.